Fig. 1.

Simulated time-course of log₁₀-transformed BCR::ABL1^IS for asciminib 40 mg b.i.d. and 80 mg q.d. in patients not harboring the T315I mutation: all patients (a) and patients stratified by number of prior TKIs and baseline BCR::ABL1^IS levels (b). The black line represents the median over the 100 replicates of the 50th percentile of BCR::ABL1^IS. The darker shaded area represents the median of 25th and 75th percentiles of BCR::ABL1^IS, and the lighter shaded area is the median of 10th and 90th percentiles of BCR::ABL1^IS. b.i.d. twice daily, q.d. once daily, TKI tyrosine kinase inhibitor